Printer Friendly

DANIEL HOTH, M.D., FORMER NIH OFFICIAL, JOINS CELL GENESYS

 FOSTER CITY, Calif., June 29 /PRNewswire/ -- Daniel F. Hoth, M.D., yesterday joined Cell Genesys, Inc. (NASDAQ: CEGE) as senior vice president and chief medical officer. In this role, Hoth will contribute broadly to the company's strategic decision-making process and to the overall management of company operations and he will have direct responsibility for clinical research and regulatory affairs. Hoth is former director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
 "As Cell Genesys' research programs move forward into product development, we are fortunate to have someone with the stature and broad experience of Dan Hoth join our senior management team," said Stephen A. Sherwin, M.D., president and chief executive officer. "Dr. Hoth's leadership in building the Division of AIDS into one of the most comprehensive research organizations in the country has given him a wealth of experience in clinical trial design and regulatory affairs, drug discovery and development, and the overall management of research and development activities," Sherwin said.
 "I am very excited to be a part of a company which is at the cutting edge of developing innovative therapeutic products," said Daniel F. Hoth, M.D., senior vice president and chief medical officer. "In my opinion, the combination of broadly-applicable technology, management experience and scientific expertise will be the key ingredients to the future success of Cell Genesys," Hoth said.
 Hoth, 47, who announced in January that he would leave his government position, had been with the NIH for the past 13 years, the last six years as director of the Division of AIDS, which is responsible for providing leadership to AIDS research sponsored by the NIAID -- a majority of the AIDS research in the country. During Hoth's tenure, the Division's budget grew to $325 million and the staff increased to 140 and the AIDS Clinical Trials Group (ACTG), which has more than 100 active clinical trials, was established.
 Prior to moving to the Division of AIDS, Hoth was at the National Cancer Institute (NCI) for seven years, most recently as chief of the Investigational Drug Branch, where he was responsible for the clinical development of drugs sponsored by the NCI, also an agency of the NIH.
 Before joining the NIH, Hoth served for three years on the faculty of the Division of Medical Oncology at Georgetown University School of Medicine, where he earned his medical degree. He completed his undergraduate work at Franklin and Marshall College in Lancaster, Penn.
 Hoth is an author on more than 70 scientific papers. He belongs to the American Society of Clinical Oncology, the American Society for Clinical Pharmacology and Therapeutics, the Society for Clinical Trials, and the Infectious Diseases Society of America.
 Cell Genesys, which became a publicly traded company last February, is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products. The company plans to begin human clinical trials of its first potential products early next year.
 -0- 6/29/93
 /CONTACT: Jack Murphy, 415-358-9600, ext. 238, for Cell Genesys/
 (CEGE)


CO: Cell Genesys, Inc. ST: California IN: HEA SU: PER

TM -- NY014 -- 6561 06/29/93 08:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:582
Previous Article:NEWTON TO HAVE SEAMLESS CONNECTION TO BOTH PC AND MACINTOSH
Next Article:ALDUS ANNOUNCES INFOPUBLISHER DATABASE ADDITION FOR PAGEMAKER
Topics:


Related Articles
SARALYNN MANDEL JOINS CELL GENESYS AS DIRECTOR OF INTELLECTUAL PROPERTY
DR. KRISZTINA ZSEBO JOINS CELL GENESYS AS DIRECTOR OF RESEARCH FOR CELLULAR THERAPY
CELL GENESYS SCIENTISTS DEVELOP METHOD FOR INTRODUCING LARGE HUMAN GENES INTO MICE
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
CELL GENESYS PROMOTES KRISZTINA ZSEBO, PH.D., TO VICE PRESIDENT OF PRODUCT DEVELOPMENT
CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS
KATHLEEN GLAUB JOINS CELL GENESYS AS CHIEF FINANCIAL OFFICER
HIGH EFFICIENCY GENE TRANSFER IN HUMAN BLOOD CELLS REPORTED BY CELL GENESYS SCIENTISTS
KILLER T CELLS REPORTED AS A POTENTIAL GENE THERAPY FOR VIRAL DISEASES AND CANCER
Cell Genesys and Somatix Agree to Merge

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters